Last reviewed · How we verify

Sildenafil (Viagra) — Competitive Intelligence Brief

Sildenafil (Viagra) (Sildenafil (Viagra)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase-5 (PDE-5) inhibitor. Area: Urology / Sexual Health.

marketed Phosphodiesterase-5 (PDE-5) inhibitor PDE-5 (phosphodiesterase type 5) Urology / Sexual Health Small molecule Live · refreshed every 30 min

Target snapshot

Sildenafil (Viagra) (Sildenafil (Viagra)) — Charles Drew University of Medicine and Science. Sildenafil inhibits phosphodiesterase-5 (PDE-5) in the corpus cavernosum, increasing cyclic GMP levels and promoting smooth muscle relaxation and vasodilation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sildenafil (Viagra) TARGET Sildenafil (Viagra) Charles Drew University of Medicine and Science marketed Phosphodiesterase-5 (PDE-5) inhibitor PDE-5 (phosphodiesterase type 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase-5 (PDE-5) inhibitor class)

  1. Charles Drew University of Medicine and Science · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sildenafil (Viagra) — Competitive Intelligence Brief. https://druglandscape.com/ci/sildenafil-viagra. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: